Pharmacie sans ordonnance livraison rapide 24h: acheter viagra en ligne en France.

Alabama

LRI CLINICAL TRIALS LIST BY STATE/CITY

Many clinical trials for lupus are starting up around the country. The following list
represents a number of studies that the LRI has been notified or is aware of, and is sorted
by location to make it easy to see what’s happening in your area.
While no one source is comprehensive, extensive trial listings also are available on
clinicaltrials.gov and on the LRI Clinical Resources center developed in partnership with
Thomson CenterWatch.
If you see a trial that interests you, scroll down to the bottom for contact information. Do
not contact the Lupus Research Institute for study details.
Please visit back soon, as a number of major clinical trials are starting soon, and trial
locations currently are being determined.

Alabama
Birmingham: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis
Huntsville: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

La Jolla: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Los Angeles: Triptorelin for Ovary Protection in Childhood Onset Lupus
Los Angeles: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

San Francisco: Treating Systemic Lupus Erythematosus (SLE) Patients with
CTLA4-IgG4m (RG2077)

San Francisco: ALMS—Aspreva Lupus Management Study of
Mycophenolate Mofetil (MMF) in Lupus Nephritis

San Leandro: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis


Denver - Epratuzumab in Systemic Lupus Erythematosus – Study
Denver - Cognitive Function in SLE: MRI and MRS Correlates

Miami: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Atlanta: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Atlanta: Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Chicago: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Chicago: Triptorelin for Ovary Protection in Childhood Onset Lupus

Muncie: Antiphospholipid Syndrome Collaborative Registry (APSCORE)
New Orleans: Ultraviolet A-1 Light Therapy for SLE
Baltimore: Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Baltimore: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Bethesda: Monoclonal Antibody to IL-6 Receptor
Bethesda: Sirolimus Therapy in Ideopathic and Lupus Membranous
Nephrology
Bethesda: Pathogenesis and Natural History of SLE
Bethesda: Lymphocyte Depletion and Stem Cell Transplantation to Treat
Severe SLE

Boston: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Ann Arbour: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Rochester: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis


Columbia: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York Brooklyn: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Lake Success: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Pharmacokinetics Study of Epratuzumab in Systemic Lupus
Erythematosus

Treating Systemic Lupus Erythematosus (SLE) Patients with
CTLA4-IgG4m (RG2077)

Triptorelin for Ovary Protection in Childhood Onset Lupus
ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis


North Carolina
Chapel Hill: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis.

Chapel Hill: Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Durham: Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Durham: Atherosclerosis Prevention Using Atrovistatin in Children with SLE
(APPLE)

Cinncinati: Triptorelin for Ovary Protection in Childhood Onset Lupus
Cleveland: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Columbus: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Columbus: Triptorelin for Ovary Protection in Childhood Onset Lupus
Oklahoma City: ALMS—Aspreva Lupus Management Study of
Mycophenolate Mofetil (MMF) in Lupus Nephritis

Anti-CD20 (Rituxan)
Philadelphia: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis.

Pittsburgh: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

Pittsburgh: Pharmacokinetics Study of Epratuzumab in Systemic Lupus
Erythematosus

Charleston: Pharmacokinetics Study of Epratuzumab in Systemic Lupus
Erythematosus
Charleston: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis.

Dallas: ALMS—Aspreva Lupus Management Study of Mycophenolate
Mofetil (MMF) in Lupus Nephritis

San Antonio: Antiphospholipid Syndrome Collaborative Registry
(APSCORE)

Salt Lake City: Antiphospholipid Syndrome Collaborative Registry
(APSCORE)

Seattle:
- - Triptorelin for Ovary Protection in Childhood Onset Lupus

Milwaukee: Triptorelin for Ovary Protection in Childhood Onset Lupus

Wyoming

LRI List of Clinical Trials

ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in
Lupus Nephritis.

Sponsor: Aspreva Phamaceuticals (as part of the Roche-Aspreva Collaboration
Agreement)
Seeking Volunteers: Persons with a diagnosis of lupus nephritis requiring
immunosuppressive therapy.
Contact Info: medinfo@aspreva.com

Anti-CD20 (Rituxan)
Sponsor: Genentech/IDEC Pharmaceuticals
Seeking Volunteers: People age 16 to 75 with moderate to severe lupus
Lupus patients with organ involvement
Contact Info: Genentech Clinical Trial Information Support Line 888-662-6728; many
trial sites are currently being determined. In Philadelphia: Felecia 215-615-4306.
Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Sponsor: National Institutes of Health/NIAMS, Bethesda, MD
Seeking Volunteers: People with antiphospholipid antibodies to joint a national disease
registery.
Contact info: Robert S. Roubey, M., or Gail Buxton: 919-966-0572; 800-411-1222;

Atherosclerosis Prevention Using Atrovistatin in Children with SLE (APPLE)
Sponsor: National Institutes of Health/NIAMS Bethesda, MD
Seeking Volunteers: Children with lupus under age 19.
Contact info: Craig McLendon 919-668-8140

Cognitive Function in SLE: MRI and MRS Correlates
Sponsor: National Jewish Medical and Research Center; University of Colorado Health
Sciences Center, Denver CO (funded by NIH/NIAMS)
Seeking Volunteers: Individuals between ages 18-59 with a diagnosis of SLE, either with
and without cognitive dysfunction; no history of major neurologic (ie, head injury, stroke,
seizures) or psychiatric disorders.
Contact info: Elizabeth Kozora, PhD, ABPP 303-398-1141;
Epratuzumab in Systemic Lupus Erythematosus - Pharmacokinetics Study
Sponsor: Immunomedics, Inc.
Seeking Volunteers: Persons age 18 and above who have had SLE for at least 6 months
prior to study, has at least one elevated autoantibody at study entery, and has moderaly
active SLE disease at study entry.
Contact info: Heather Horne 973-727-7589

Epratuzumab in Systemic Lupus Erythematosus – Study
Sponsor: Immunomedics, Inc.
Seeking Volunteers: Persons age 18 and above who has had SLE for at least 6 months
with at least one elevated lupus-associated antibody, and has new onset severe lupus
disease flare in at least one organ/system, OR has a moderate lupus disease flare in
several body ogans/systems.
Contact info: Sally Klemm, RN. 973-605-8022

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe SLE
Sponsor: National Institutes of Health/NCI, Bethesda, MD
Seeking Volunteers: Patients between ages of 15 and 40 with severe lupus
Contact info: Patients Recruitment and Public Liaison Office: 800-411-1222;

Sirolimus Therapy in Ideopathic and Lupus Membranous Nephrology
Sponsor: Wyeth –Ayerst Laboratories & National Institutes of Health/NIDDK, Bethesda,
MD
Seeking Volunteers: Persons 13 or older with persistent proteinuria despite standard
treatment for at least one month with angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker.
Contact info: Patients Recruitment and Public Liaison Office: 800-411-1222;

Monoclonal Antibody to IL-6 Receptor
Sponsor: National Institutes of Health/NIAMS, Bethesda, MD
Seeking Volunteers: People with mild to moderate SLE.
Contact info: Patient Recruitment and Public Liaison Office 800-411-1222;
prpl@mail.cc.nih.gov
Pathogenesis and Natural History of SLE
Sponsor: National Institutes of Health/NIAMS, Bethesda, MD
Seeking Volunteers: People 10 years and older with known or suspected SLE, and their
relatives.
Contact info: Patient Recruitment and Public Liaison Office 800-411-1222;
prpl@mail.cc.nih.gov
Sponsor: Fred Hutchinson Cancer Research Center, Seattle WA
Seeking Volunteers: Individuals between 2 and 18, with at least one ACR criterion for
severe juvenile rheumatoid arthritis, juvenile SLE, systemic sclerosis dermatomyositis.
Contact info: Ann Woolfrey, MD. 206-667-4453
Treating Systemic Lupus Erythematosus (SLE) Patients with CTLA4-IgG4m
(RG2077)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID), Immune
Tolerance Network
Seeking Volunteers: Persons age 18 and above with lupus nephritis. Also, people with
SLE and on concurrent treatment with intravenous cyclophosphamide for certain
manifestations of lupus. Also: stable medication regiment for at least 4 weeks prior to
study entry, weight between 88.2 lb and 275.6 lb, and willing to use acceptable forms of
contraception.
Contact info: San Francisco: 415-502-1886; New York City: 212-305-9986

Triptorelin for Ovary Protection in Childhood Onset Lupus
Sponsor: FDA Office of Orphan Products Development
Seeking Volunteers: Females between ages 9 and 21 years, not pregnant, who have lupus
and are newly requiring IV cyclophosphamide.
Contact info: Hermine Brunner, MD. 513-636-5484;
Ultraviolet A-1 Light Therapy for SLE
Sponsor: National Center for Research Resources/Louisiana State University, New
Orleans LA
Seeking Bolunteers: Patients age 15-70 with symptomatic SLE
Contact info: GRCR 504-568-4609
Disclaimer
This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted. Posted on June 22, 2005.

Source: http://www.lupusresearchinstitute.org/downloads/lri_clinical_trials.pdf

midwivescollective.ca

Inappropriate use of randomised trials to evaluate complex phenomena: case study of vaginal breech delivery Updated information and services can be found at: References This article cites 25 articles, 8 of which can be accessed free at: Rapid responses 8 rapid responses have been posted to this article, which you can access forfree at: Email alerting Receive free email alerts

emdristanbul.com

Copyright Ó Blackwell Munksgaard 2004Ephedra alkaloids and brief relapse inEMDR-treated obsessive compulsivedisorderFluvoxamine with no compulsive hand washing and no mooddisturbance. In his review of the adverse effects of some herbal medicines,While there is still debate about the mechanism of action ofErnst (1) draws attention to reports that ma-huang, a herbalEMDR in post-traumatic s

Copyright © 2010-2014 Sedative Dosing Pdf